Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) for VIMKUNYA® ...

AN2 Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, ...

Washington has an opportunity to help tens of millions.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.

Two years of reporting at a permanent supportive housing building in New York show the successes and limitations of the ...

Researchers from Memorial Sloan Kettering Cancer Center and the University of California, Los Angeles, identified that ...

UB researchers have compiled a list of words physicians should never say to patients with complex, chronic disorders that are ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.

today announced that data from its Phase 2a TrIuMPH trial of EBX-102-02 in 122 adults with IBS-C has been selected for a late-breaking oral presentation at Digestive Disease Week® (DDW ...

EnteroBiotix is a clinical-stage biotechnology company developing microbiome-based therapeutics for irritable bowel syndrome (IBS) and other gastrointestinal and hepatic indications. Using its ...

The ongoing total siege imposed on the Gaza Strip since early March 2025 has worsened the suffering of all its residents, ...

Chronic kidney disease (CKD ... The most severe form is end-stage renal disease. DNA damage in renal proximal tubular epithelial cells may lead to impaired kidney function but the biological ...